PT Staff

Products include acne patches and immune boosting power.

Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl; Sanofi] is high-sustained factor VIII replacement therapy indicated for routine prophylaxis and on-demand treatment to control bleeding episodes and for perioperative management in adults and children with hemophilia A.

Extended infusion piperacillin/tazobactam was associated with lower odds of 14-day mortality compared to standard infusion piperacillin/tazobactam.

Elranatamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody that may become the next standard of care for multiple myeloma, according to researchers.

Products range from Parkinson disease treatment to medication for epilepsy.

Products include medications for depressive disorder and migraines.

The FDA approved darolutamide in 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer based improved metastasis-free survival.

Austedo XR will be available in 3 extended-release tablet strengths, which provides an updated regimen that may result in a lower pill count for patients.

Expanded indication for abrocitinib (Cibinqo; Pfizer Inc) includes patients 12 to <18 years of age with refractory, moderate-to-severe atopic dermatitis that is not adequately controlled with other systemic medications.

Aflibercept injection is also indicted for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Single nasal swab test can determine whether a patient has COVID-19, influenza, respiratory syncytial virus, or a combination of these viruses in as little as 2 hours.

Sacituzumab govitecan-hziy (Trodelvy) is a conjugated Trop-2-directed antibody and topoisomerase inhibitor previously approved for patients with triple-negative breast cancer.

Daprodustat (Jesduvroq, GSK) is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor to gain approval in the United States.

Amjevita is approved for all indications of reference Humira except for hidradenitis suppurativa.

Pembrolizumab approved as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer.

Products include drugs for patients with stroke, bacterial infections, and acute pain.

An organ transplant is a known risk factor for C. difficile infection, however, data are lacking on how the infection affects those who underwent an intestinal transplant.

Zilucoplan is among highlighted products of the month.

Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa; BeiGene USA, Inc) approved for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 inhibitor that inhibits cytokine signaling in psoriasis pathogenesis.

Research shows that some unsuccessful switches from reference products to biosimilars may be attributed to patient perceptions of reduced efficacy and safety.

Molecular methods such as polymerase chain reaction show promise in monitoring the patient environment in hospitals and could help to provide reassurance prior to admission.

Products range from natural eye relief to sleep aid.

YLB113 (Nepexto) produced significantly lower injection site reactions and injection site erythema compared with etanercept in patients with rheumatoid arthritis.

Patients with cystic fibrosis are typically administered antibiotics throughout their lives, which can increase the risk for C difficile infections.

Approximately half of patients with heart failure do not require an implantable monitoring device or do not qualify for thoracic monitoring.

There have been more than 80,000 monkeypox cases reported worldwide.

Greater prevalence of hand eczema among health care professionals working in COVID-19 units linked to increased hand sanitation habits.

Study finds a strong decline in hepatitis C incidence in the years immediately following broad access to direct-acting antiviral drugs.

Clinical trials show that patients with atopic dermatitis experienced improved symptoms with dupilumab starting at 8 weeks, with maximum effect around 12 weeks.